1. Cancer Cells Employ Nuclear Caspase-8 to Overcome the p53-Dependent G2/M Checkpoint through Cleavage of USP28.
- Author
-
Müller I, Strozyk E, Schindler S, Beissert S, Oo HZ, Sauter T, Lucarelli P, Raeth S, Hausser A, Al Nakouzi N, Fazli L, Gleave ME, Liu H, Simon HU, Walczak H, Green DR, Bartek J, Daugaard M, and Kulms D
- Subjects
- Antineoplastic Agents pharmacology, Apoptosis, Caspase 8 genetics, Cell Nucleus drug effects, Cell Nucleus genetics, Cell Nucleus pathology, Drug Resistance, Neoplasm, Female, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic, HCT116 Cells, HeLa Cells, Humans, MCF-7 Cells, Male, Neoplasms drug therapy, Neoplasms genetics, Neoplasms pathology, PC-3 Cells, Protein Stability, Signal Transduction, Tumor Cells, Cultured, Tumor Suppressor Protein p53 genetics, Ubiquitin Thiolesterase genetics, Caspase 8 metabolism, Cell Nucleus enzymology, Cell Proliferation drug effects, G2 Phase Cell Cycle Checkpoints drug effects, Neoplasms enzymology, Tumor Suppressor Protein p53 metabolism, Ubiquitin Thiolesterase metabolism
- Abstract
Cytosolic caspase-8 is a mediator of death receptor signaling. While caspase-8 expression is lost in some tumors, it is increased in others, indicating a conditional pro-survival function of caspase-8 in cancer. Here, we show that tumor cells employ DNA-damage-induced nuclear caspase-8 to override the p53-dependent G2/M cell-cycle checkpoint. Caspase-8 is upregulated and localized to the nucleus in multiple human cancers, correlating with treatment resistance and poor clinical outcome. Depletion of caspase-8 causes G2/M arrest, stabilization of p53, and induction of p53-dependent intrinsic apoptosis in tumor cells. In the nucleus, caspase-8 cleaves and inactivates the ubiquitin-specific peptidase 28 (USP28), preventing USP28 from de-ubiquitinating and stabilizing wild-type p53. This results in de facto p53 protein loss, switching cell fate from apoptosis toward mitosis. In summary, our work identifies a non-canonical role of caspase-8 exploited by cancer cells to override the p53-dependent G2/M cell-cycle checkpoint., Competing Interests: Declaration of Interests The authors declare no competing interests., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF